| Automatic bolus and adaptive basal algorithm for the artificial pancreatic β-cell. | |
| | |
MedLine Citation:
|
PMID: 20879966 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
BACKGROUND: The current basal and bolus insulin pump therapy is dependent on user intervention; because of its open-loop nature, the therapy does not accommodate insulin variability and unmeasured meal disturbances. To conquer these challenges, an automatic bolus and adaptive basal (ABAB) therapy is proposed to regulate glucose levels for people with type 1 diabetes mellitus. METHODS: The basal insulin profile is adjusted by the proposed algorithm every 30 min based on interstitial glucose level and its rate of change. An automated bolus is suggested by the system if a meal is detected or a hyperglycemia event occurs. A conservative insulin bolus is administered, the size of which is determined based on glucose prediction and the subject-specific correction factor. One hour later, the algorithm checks whether another bolus is needed. To prevent overdelivery, insulin-on-board is used as a safety constraint. RESULTS: The ABAB therapy was compared with the optimal open-loop therapy and missed-bolus scenario on 100 adult subjects from the Food and Drug Administration-accepted University of Virginia/Padova Metabolic Simulator. The ABAB therapy presented superior performance according to the control-variability grid analysis. In addition, the ABAB therapy shows excellent robustness to insulin sensitivity rise: the hypoglycemia percentage was only 3.3% even when insulin sensitivity was increased by 20%. Independent of user intervention, the ABAB therapy is a good candidate for the first generation of an artificial pancreas. The proposed therapy shows excellent robustness to insulin dosing mismatches. |
| | |
Authors:
|
Youqing Wang; Eyal Dassau; Howard Zisser; Lois Jovanovič; Francis J Doyle |
Related Documents
:
|
19690556 - Therapy: intensive glucose control in the icu: is sugar nice? 18588656 - Practical strategies to improve treatment of type 2 diabetes. 18050526 - Standards of care and the burden of treatment failure in type 2 diabetes. 16182826 - Pancreas transplantation for treatment of generalized allergy to human insulin in type ... 2780126 - Diabetic microangiopathy in patients with cystic fibrosis. 15585586 - Isoproterenol decreases leptin release from rat and human adipose tissue through posttr... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-09-30 |
Journal Detail:
|
Title: Diabetes technology & therapeutics Volume: 12 ISSN: 1557-8593 ISO Abbreviation: Diabetes Technol. Ther. Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-11-24 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100889084 Medline TA: Diabetes Technol Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 879-87 Citation Subset: IM |
Affiliation:
|
Department of Chemical Engineering, University of California-Santa Barbara, Santa Barbara, CA 93106, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Long-term insulin pump treatment in girls with type 1 diabetes and eating disorders--is it feasible?
Next Document: Association of cystatin-C with metabolic syndrome in normal glucose-tolerant subjects (CURES-97).